Head-to-head · Cost-Efficiency Index
Pallas Health vs Vytora Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Pallas Health
Shoppers comfortable paying a quarter at a time who want the whole cost stated before signup, and who are not looking for a month-to-month exit.
Visit Pallas HealthVytora Health
Shoppers who want flat per-dose pricing with a named pharmacy and an optional brand-name fallback, 50 states.
Visit Vytora HealthThe verdict
Vytora Health takes it, leading the Cost-Efficiency Index 76 to 74. Vytora Health (Wasef Health, PC) is a 50-state-plus-DC telehealth platform selling flat-rate compounded semaglutide and tirzepatide alongside retail-priced brand-name Mounjaro and Zepbound ($1,399/mo each). Pallas Health still earns a C — Shoppers comfortable paying a quarter at a time who want the whole cost stated before signup, and who are not looking for a month-to-month exit.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Vytora Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Pallas Health | Vytora Health |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 76/100 |
| Semaglutide / mo | $199/mo average — Pallas's own figure for $597 billed every 12 weeks, its only cadence; $139 covers the first 4 weeks | $179/mo (all doses, compounded) |
| Tirzepatide / mo | $299/mo average — Pallas's own figure for $897 billed every 12 weeks, its only cadence; $179 covers the first 4 weeks | $199/mo (all doses, 3-month plan, compounded) |
| Semaglutide / yr (modeled) | $2,388 | $2,148 |
| Tirzepatide / yr (modeled) | $3,588 | $2,388 |
| Coverage | Most states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #47 | #51 |
Pallas Health
74/100Where the value is
- Both molecules are priced publicly, with the charged block stated rather than only a monthly average
- A genuinely reduced first cycle — $139 semaglutide and $179 tirzepatide for the first four weeks
- Runs a Spanish-language lander as well as the English site, which most of this field does not
The tradeoffs
- There is no monthly rung. The only cadence is a 12-week block paid up front — $597 or $897 — so the advertised 'per month' figure is arithmetic rather than a payment anyone makes
- A 12-week cycle is 4.33 charges a year, not 4, so a year costs more than four times the block
Vytora Health
76/100Where the value is
- Semaglutide pricing is genuinely flat across all doses, not a 'starting at' floor
- 50 states plus DC covered, with per-state video-vs-audio requirements disclosed rather than hidden
- Both compounded and retail brand-name (Mounjaro, Zepbound) options on one platform
The tradeoffs
- The site's own FAQ and pricing page disagree on the 1-month tirzepatide price ($199 vs $249) — get the number confirmed at checkout before assuming either figure
- Brand-name Mounjaro/Zepbound at $1,399/mo is essentially full retail
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.